Literature DB >> 31151988

Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia.

Amaliris Guerra1, Paraskevi Rea Oikonomidou1, Sayantani Sinha1, Jianbing Zhang1, Vania Lo Presti1, Callum R Hamilton1, Laura Breda1, Carla Casu1, Ping La1, Ana C Martins2, Anoop K Sendamarai3, Mark Fleming3, Stefano Rivella1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31151988      PMCID： PMC6688431          DOI： 10.1182/blood.2019001057

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  21 in total

1.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

2.  Targeting a new regulator of erythropoiesis to alleviate anemia.

Authors:  Robert F Paulson
Journal:  Nat Med       Date:  2014-04       Impact factor: 53.440

3.  Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle.

Authors:  Manisha Sinha; Young C Jang; Juhyun Oh; Danika Khong; Elizabeth Y Wu; Rohan Manohar; Christine Miller; Samuel G Regalado; Francesco S Loffredo; James R Pancoast; Michael F Hirshman; Jessica Lebowitz; Jennifer L Shadrach; Massimiliano Cerletti; Mi-Jeong Kim; Thomas Serwold; Laurie J Goodyear; Bernard Rosner; Richard T Lee; Amy J Wagers
Journal:  Science       Date:  2014-05-05       Impact factor: 47.728

4.  Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment.

Authors:  S Ogilvy; D Metcalf; L Gibson; M L Bath; A W Harris; J M Adams
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

5.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

6.  Global epidemiology of haemoglobin disorders and derived service indicators.

Authors:  Bernadette Modell; Matthew Darlison
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

7.  A mouse model for visualization and conditional mutations in the erythroid lineage.

Authors:  Achim C Heinrich; Roberta Pelanda; Ursula Klingmüller
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

8.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

9.  A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.

Authors:  Kenneth M Attie; Mark J Allison; Ty McClure; Ingrid E Boyd; Dawn M Wilson; Amelia E Pearsall; Matthew L Sherman
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

10.  Redundancy of myostatin and growth/differentiation factor 11 function.

Authors:  Alexandra C McPherron; Thanh V Huynh; Se-Jin Lee
Journal:  BMC Dev Biol       Date:  2009-03-19       Impact factor: 1.978
View more
  16 in total

1.  Steady-state and regenerative hematopoiesis occurs normally in mice in the absence of GDF11.

Authors:  Jill M Goldstein; Hilal Sengul; Kathleen A Messemer; Marcos Fernández-Alfara; Jessica C Garbern; Amy C Kristl; Richard T Lee; Amy J Wagers
Journal:  Blood       Date:  2019-11-14       Impact factor: 22.113

2.  Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors:  Prithviraj Bose
Journal:  Expert Opin Orphan Drugs       Date:  2019-09-24       Impact factor: 0.694

Review 3.  Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.

Authors:  Amit Verma; Rajasekhar Nvs Suragani; Srinivas Aluri; Nishi Shah; Tushar D Bhagat; Mark J Alexander; Rami Komrokji; Ravi Kumar
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

4.  The use of luspatercept for thalassemia in adults.

Authors:  Maria Domenica Cappellini; Ali T Taher
Journal:  Blood Adv       Date:  2021-01-12

Review 5.  Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.

Authors:  Filomena Longo; Andrea Piolatto; Giovanni Battista Ferrero; Antonio Piga
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 6.  The Role of Iron in Benign and Malignant Hematopoiesis.

Authors:  Sayantani Sinha; Joana Pereira-Reis; Amaliris Guerra; Stefano Rivella; Delfim Duarte
Journal:  Antioxid Redox Signal       Date:  2021-01-07       Impact factor: 7.468

Review 7.  Controversies on the Consequences of Iron Overload and Chelation in MDS.

Authors:  Francesca Vinchi; Saskia Hell; Uwe Platzbecker
Journal:  Hemasphere       Date:  2020-05-27

Review 8.  Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.

Authors:  Irene Motta; Rayan Bou-Fakhredin; Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

Review 9.  EnvIRONmental Aspects in Myelodysplastic Syndrome.

Authors:  Verena Petzer; Igor Theurl; Günter Weiss; Dominik Wolf
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

Review 10.  SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.